Antibody-mediated transplant rejection involves B cell and plasma cell activation resulting in the generation of donor-specific antibodies, which bind to HLA and/or non-HLA molecules on the endothelium. Preformed donor–specific HLA antibodies resulting in hyperacute rejection were first detected in 1969 by the complement-dependent cytotoxicitycrossmatchassay. The presence of pre-formed and de novo DSA, specific to donor/recipient mismatches are major risk factors for antibody-mediated rejection, which results in both acute and chronic transplant injury and is the primary cause of accelerated early and late allograft loss. Almost a third of patients who are waitlisted for transplantation may have a degree of anti-HLA antibodies detected. The usual route for sensitisation towards HLA antigens occurs in three instances; pregnancy, post blood transfusion and prior transplantation. Preformed antibodies increase the chances of immunological failure of the allograft by causing positive crossmatches and, thereby, result in the exclusion of donors. For sensitised patients, successful transplantation is possible by employing strategies such as desensitisation, paired exchange and acceptable mismatching.
Panel reactive antibody
The degree of cytotoxicity is expressed as percentage PRA. It is a tool that can be employed to approximate the risk of a given recipient of having a positive crossmatch. This is to a likely organ donor taken from a similar population. The limitations of this method are that PRA percent can be different numerically without a corresponding change in the type or amount of antibody. This largely depends on the cell panel used which are commercially produced and may not truly represent the population. HLA frequencies and racial differencesneed to be factored in but cannot be done. Moreover, significant false positive results can be produced due to non-HLA antibodies, autoantibodies and nonspecific IgM antibodies. Similarly, false negative results are possible as this is purely complement dependent that requires higher antibody titres to be activated. The lack of a complement activation simply due to low titres allows a true antibody to be hidden.
Cross-match test
Patel and Terasaki in 1969 demonstrated the efficacy of complement-dependent lymphocytotoxic cross-match in defining immunologic risk in renal transplantation. This became the standard method, still used today, for graft allocation. With PRA that identifies several antibodies to a potential cluster of donors, the crossmatch will identify if a recipient had antibodies to a specific donor of interest. It became clear with time that it did not identify all preexisting donor-specific HLA antibodies. In recent years, techniques for detection of HLA antibodies have become more sensitive with the introduction of solid-phase assays, including ELISA.
